Product Description: Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 35, No. 4, 2021.
CAS Number: 2473240-98-9
Molecular Weight: N/A
Research Area: Inflammation/Immunology
Solubility: H2O
Target: TGF-beta/Smad